Literature DB >> 11377818

Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects.

R J Bollag1, Q Zhong, K H Ding, P Phillips, L Zhong, F Qin, J Cranford, A L Mulloy, R Cameron, C M Isales.   

Abstract

Glucose-dependent insulinotropic peptide (GIP) is a gut-derived hormone known to be important in modulating glucose-induced insulin secretion. In addition, GIP receptors are widely distributed and may have effects on multiple other tissues: fat cells, adrenal glands, endothelium and brain. We have demonstrated recently that GIP also has anabolic effects on bone-derived cells. We now demonstrate that GIP administration prevents the bone loss associated with ovariectomy. We propose that GIP plays a unique role in signaling the bone about nutrient availability, indicating the importance of the gut hormones in directing absorbed nutrients to the bone, and suggesting the concept of an 'entero-osseous axis'. Thus, GIP plays an integrative role helping coordinate efficient and targeted nutrient absorption and distribution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377818     DOI: 10.1016/s0303-7207(01)00405-1

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  28 in total

1.  c-Fos induction by gut hormones and extracellular ATP in osteoblastic-like cell lines.

Authors:  Elda Leonor Pacheco-Pantoja; Jane P Dillon; Peter J M Wilson; William D Fraser; James A Gallagher
Journal:  Purinergic Signal       Date:  2016-07-20       Impact factor: 3.765

Review 2.  Relationships between fat and bone.

Authors:  I R Reid
Journal:  Osteoporos Int       Date:  2007-10-27       Impact factor: 4.507

Review 3.  Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass.

Authors:  M P Hage; G El-Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-09-06       Impact factor: 4.507

4.  Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.

Authors:  Kimberly A Kyle; Thomas L Willett; Laurie L Baggio; Daniel J Drucker; Marc D Grynpas
Journal:  Endocrinology       Date:  2010-12-22       Impact factor: 4.736

5.  Attenuation by incretins of thyroid hormone-stimulated osteocalcin synthesis in osteoblasts.

Authors:  Shingo Kainuma; Haruhiko Tokuda; Kazuhiko Fujita; Tetsu Kawabata; Go Sakai; Rie Matsushima-Nishiwaki; Atsushi Harada; Osamu Kozawa; Takanobu Otsuka
Journal:  Biomed Rep       Date:  2016-11-01

6.  The aromatic amino acid tryptophan stimulates skeletal muscle IGF1/p70s6k/mTor signaling in vivo and the expression of myogenic genes in vitro.

Authors:  Amy Dukes; Colleen Davis; Mona El Refaey; Sunil Upadhyay; Sarah Mork; Phonepasong Arounleut; Maribeth H Johnson; William D Hill; Carlos M Isales; Mark W Hamrick
Journal:  Nutrition       Date:  2015-03-17       Impact factor: 4.008

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa.

Authors:  Monica H Wojcik; Erinne Meenaghan; Elizabeth A Lawson; Madhusmita Misra; Anne Klibanski; Karen K Miller
Journal:  Bone       Date:  2009-11-18       Impact factor: 4.398

9.  Impact of glucose-dependent insulinotropic peptide on age-induced bone loss.

Authors:  Ke-Hong Ding; Xing-Ming Shi; Qing Zhong; Baolin Kang; Ding Xie; Wendy B Bollag; Roni J Bollag; William Hill; Walter Washington; Qing-Sheng Mi; Karl Insogna; Norman Chutkan; Mark Hamrick; Carlos M Isales
Journal:  J Bone Miner Res       Date:  2008-04       Impact factor: 6.741

10.  Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.

Authors:  Elena Ceccarelli; Elisa G Guarino; Daniela Merlotti; Aurora Patti; Luigi Gennari; Ranuccio Nuti; Francesco Dotta
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.